



CoreTherm® - Market share growing rapidly in Sweden

The National Board of Health and Welfare has published statistics on surgeries in outpatient and inpatient care in Sweden in 2021. [1] 18%, of the patients with benign prostatic hyperplasia (BPE /BPH) who underwent any surgery/procedure (KED) during the year, received transurethral microwave therapy (TUMT, KED72).

The total number of resections and other flow-promoting interventions (KED) for BPH patients in Sweden amounted to 4,905 in 2021, which is an increase from the pandemic year 2020 but just over 6% fewer than in 2019. However, despite increasing older male population, flow-promoting interventions have declined sharply in Sweden over the past 30 years since peaks in the late 1980s when 12-13,000 procedures were performed annually.

Transurethral microwave therapy (TUMT) is the medical terminology for the basic methodology of Coretherm® Concept, ProstaLund's further developed method for the treatment of benign prostatic hyperplasia. The trend continues, TUMT accounts for an increasing share of the BPE interventions performed. From 8% in 2018, about 12% in 2019, about 14% in 2020 to almost 18% in 2021. According to the National Board of Health and Welfare's figures, TUMT treatments (CoreTherm®) were performed on 867 men in 2021. TURP remains the most common intervention in Sweden, but the number continues to decrease, just over 2,900 were performed during the previous year.

Johan Wennerholm, CEO of ProstaLund, comments: "We continue to strengthen CoreTherm's position in the Swedish market and I am delighted with the almost 900 Swedish men who received our treatment last year. It is also clear that healthcare is increasingly unable to operate on this patient group and our resource-efficient and fast treatment is the solution. More than 2,500 men are currently waiting for surgery and in addition there are more than 215,000 men who daily try to relieve their symptoms with drugs and among these many would surely like to get a cure with CoreTherm®"

[1] <https://www.socialstyrelsen.se/statistik-och-data/statistik/statistikdatabasen/>

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
29 August 2022 13:00:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Image Attachments

KED72_Transuretral_Mikrovågsterapi

KED72_Transuretral_Mikrovågsterapi

Attachments

CoreTherm® - Market share growing rapidly in Sweden